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Abstract: Adaptation to hypoxia is a common feature in solid tumors orchestrated by
oxygen-dependent and independent upregulation of the hypoxia-inducible factor-1α (HIF-1α).
We unveiled that G protein-coupled receptor kinase (GRK2), known to be overexpressed in certain
tumors, fosters this hypoxic pathway via phosphorylation of the mRNA-binding protein HuR, a central
HIF-1α modulator. GRK2-mediated HuR phosphorylation increases the total levels and cytoplasmic
shuttling of HuR in response to hypoxia, and GRK2-phosphodefective HuR mutants show defective
cytosolic accumulation and lower binding to HIF-1α mRNA in hypoxic Hela cells. Interestingly,
enhanced GRK2 and HuR expression correlate in luminal breast cancer patients. GRK2 also promotes
the HuR/HIF-1α axis and VEGF-C accumulation in normoxic MCF7 breast luminal cancer cells and
is required for the induction of HuR/HIF1-α in response to adrenergic stress. Our results point
to a relevant role of the GRK2/HuR/HIF-1α module in the adaptation of malignant cells to tumor
microenvironment-related stresses.
Keywords: hypoxia; β-adrenergic signaling; breast cancer; mRNA regulation; nucleocytoplasmic
shuttling; GRK2; HuR; HIF1α; VEGF
1. Introduction
Oxygen is a key factor in embryonic development and in normal tissue homeostasis, and its
shortage triggers adaptive mechanisms required for cell survival [1,2]. Hypoxia is also a hallmark of
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solid tumors that results from a leaky vasculature within the tumor and the high proliferation rate
of both cancerous cells and immune infiltrating cells [3]. Tumor-associated hypoxia correlates with
cellular resistance to chemotherapy, metastasis, and poor patient survival, indicating that hypoxia
acts as an extrinsic driver of tumor progression [4,5]. The hypoxia-inducible transcription factors
HIF-1 and HIF-2 are the main coordinators of the cellular response to low oxygen tension in both
normal and transformed cells [2,5]. HIF-1 is formed by two helix-loop-helix-PAS proteins, namely
HIF-1α and HIF-1β or ARNT. Under normoxia, HIF-1α subunits are efficiently ubiquitinated and
targeted for proteasome-dependent degradation by the multimeric SCF2 E3 ligase coupled with the
von Hippel-Lindau tumor suppressor protein VHL, which recognizes HIF subunits only after their
hidroxylation by PHD1-3, a family of oxygen-dependent prolyl-hidroxylases. In hypoxic conditions,
HIF-1α subunits are stabilized as a result of PHD inhibition and translocated to the nucleus, where they
dimerize with ARNT, in order to activate the transcription of hundreds of genes [5,6].
Interestingly, in cancerous cells, the HIF signaling pathway can also be regulated by other
environmental and intracellular signaling factors in an oxygen-independent manner, via modulation of
protein stability, gene transcription, or mRNA binding proteins such as YB-1 and HuR (Human antigen
R), which are often up-regulated in tumor contexts thereby leading to enhanced translation of HIF-1α
mRNA in normoxic and hypoxic conditions [7–9]. HIF-1α is often downstream of the activation of
different plasma membrane receptors-triggered signaling pathways, thus linking HIF-1α status to the
growth needs of cells [10–12].
Different G protein-coupled receptors (GPCRs) have been associated with the progression of
several types of tumors [13,14]. Of note, activation of GPCRs by β-adrenergic, endothelin-1 or
lysophosphatidic acid agonists has been shown to promote the stabilization of HIF proteins [12,15,16],
thus mimicking hypoxic conditions. Cumulative evidence indicates that chronic neurosympathetic
activity fosters the malignant growth and dissemination of tumor cells through direct stimulation of
β2AR receptors [17]. Several processes appear to underlie the influence of βAR on tumor progression,
including increased HIF-1α signaling and angiogenesis. Besides its role in GPCR desensitization, the G
protein-coupled receptor kinase 2 (GRK2) is emerging as a key signaling hub. GRK2 can act as a positive
effector of certain GPCR and receptor-tyrosine kinases (RTK) transduction cascades [18,19], and also
directly interacts/phosphorylates components of signaling networks involved in cell transformation [20].
We have recently shown that GRK2 expression is up-regulated in different breast cancer contexts, playing
a driving role in the acquisition of oncogenic features [21,22]. Concurrently, GRK2 downregulation
takes place in the breast tumor vessels [23]. Such opposite and cellular-specific alterations in GRK2
expression seem to be causally related, promoting a marked increase of intra-tumoral hypoxia and of
the tumor-associated macrophage-derived factor adrenomedullin, a known VHL-HIF-1 target gene.
In this report we unveil that GRK2 is a relevant modulator of the hypoxic pathway in transformed
epithelial cells via phosphorylation-dependent modulation of the mRNA-binding protein HuR, leading
to subsequent nuclear accumulation of the HIF-1α protein. Stimulation of GRK2 upon hypoxia
or adrenergic receptor activation emerges as a novel mechanism of regulation of HIF signaling in
physiological or pathological processes, such as cancer progression.
2. Results
Our previous results pointed to GRK2 as a common regulatory and transducing effector of diverse
pathways that are altered in luminal and basal breast cancer [21,22]. Remarkably, the mRNA binding
protein ELAV-like protein 1 (HuR), a key upstream modulator of HIF-1α and other targets, is also
overexpressed in these tumor contexts [24,25]. Moreover, GRK2 upregulation alters the activity of
several transcription factors in normal breast cells that are chronically stimulated with EGF [21],
whereas HuR activity changes in response to EGF [26]. A subset of EGF- and GRK2-regulated
transcription factors in such conditions can be linked to a GRK2-mediated gain-of-function of the
prolyl isomerase Pin1 [21] (Figure S1). Interestingly, other subsets can be linked to HuR (Figure
S1), since their mRNAs are either regulated or potentially targeted by this protein [27]. Altogether,
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these observations suggested a potential functional relationship between HuR and GRK2 in both tumor
and non-tumor settings.
2.1. HuR Protein Levels Positively Correlate with GRK2 Activity
We analyzed the steady-state levels of HuR protein under different GRK2 expression and activation
status contexts in Hela cells, a cellular model widely used in the functional characterization of HuR.
The protein levels of HuR directly correlated with GRK2 abundance, being significantly upregulated
in cells over-expressing the wild-type GRK2 (Hela-WT5), but down-modulated upon stable GRK2
silencing (Hela-shGRK2) (Figure 1A). Interestingly, HuR abundance remained unaltered compared
to parental Hela cells, upon stable over-expression of the catalytically inactive GRK2-K220R mutant
(Hela-K1 cells) or of GRK2-S670A, which lacks the ability to phosphorylate a subset of GRK2 substrates
(Hela-A1 cells) [21,28]. These results suggested that GRK2-mediated phosphorylation of either HuR or
an intermediate factor was involved in the regulation of HuR expression levels.
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(Hela-WT5), a mutant lacking the ability to phosphorylate a subset of GRK2 substrates (Hela-A1),
the catalytically inactive GRK2-K220R mutant (Hela-K1) or harboring stable GRK2 silencing
(Hela-shGRK2). Values are mean ± SEM from four independent experiments. * p < 0.05 vs. parental
(Student’s t-test). (B) GRK2 and GST-HuR were incubated in the presence of [γ-32P]-ATP, as detailed in
Materials and Methods. Km was estimated by double-reciprocal plot analysis of three independent
experiments. (C) Phosphorylation of GST-HuR was performed in the presence of [γ-32P]-ATP using
recombinant GRK2-WT, GRK2-S670A, or GRK2-K220R proteins, as described in Materials and Methods.
Intensity of 32P and the Coomassie bands were quantified by densitometry and plotted as a percentage of
WT GRK2-triggered 32P incorporation. Data representative of two independent experiments are shown.
*** p < 0.001 vs. parental (Student’s t-test). (D) GRK2 (50 nM) and GST-HuR, GST-HuR-T142/143A,
or GST-HuR-S197A (100 nM) were incubated in the presence of [γ-32P]-ATP, as detailed in Materials and
Methods. Intensity of the 32P and Coomassie bands was quantified by densitometry and plotted as a
percentage of GRK2-triggered 32P incorporation. The graph shows fold differences in two independent
experiments. * p < 0.05 vs. WT ** p < 0.01 vs. WT (1-way ANOVA). Detailed information about the
Western blots can be found in Figure S2.
2.2. HuR Is a GRK2 Phosphorylation Substrate
Purified GST-HuR was efficiently phosphorylated by recombinant GRK2 (Km of ~ 48 nM,
Figure 1B), similar to the well-known physiological substrates of GRK2 [28,29], whereas no
phosphorylation was observed in the recombinant GRK2-K220R (Figure 1C), indicating that HuR is a
direct target of GRK2. Consistently, a direct and preferential binding of HuR to the catalytic domain of
GRK2 was detected in the overlay assays (Figure S3A).
Akin to some GRK2 substrates such as HDAC6 [28], phosphorylation of GRK2 at the regulatory site
Ser670 seems to be required to enable kinase activity towards HuR, since the recombinant GRK2-S670A
mutant was incapable of phosphorylating HuR (Figure 1C), despite being able to fully phosphorylate
other well-established GRK2 substrates [28]. These data and those obtained in Hela-A1 cells suggest
that HuR belongs to the subset of ‘phospho-Ser670-biased’ GRK2 targets.
We identified three potential phosphorylation site(s) on the GRK2-phosphorylated GST-HuR,
by using proteomic approaches (Figure S3B). Single or double site-directed mutagenesis to alanine of
these candidate sites, followed by in vitro phosphorylation assays showed that GST-HuR-Thr-142/143A
and GST-HuRS-197A purified proteins displayed a significantly reduced phosphorylation by GRK2,
compared to the wild-type (Figure 1D), indicating that these residues are accounting for circa 75%
of total GRK2-dependent HuR phosphorylation. Interestingly, these residues are located in two key
functional and regulatory regions of the HuR protein, the second RNA-binding domain (RRM2)
(residues Thr142 and 143) and the nucleocytoplasmic localization hinge region (residue Ser197)
(Figure S3B). Phosphorylation of the hinge region and the RRM domains by different kinases has been
shown to underlie changes in HuR subcellular localization, binding affinity with mRNA, and regulation
of translational efficiency [30–34].
2.3. GRK2 Activity Modulates the Hypoxia-Induced Modulation of HuR Cellular Levels and
Cytoplasmic Shuttling
Hypoxia is a well-characterized stress known to upregulate HuR protein levels, in order to foster
HuR actions [35]. Interestingly, Hela-WT5 cells stably expressing GRK2, displayed an enhanced boost
in HuR levels upon acute exposure to low oxygen, while such HuR upregulation was absent upon
kinase downregulation (Hela-shGRK2 cells) (Figure 2A). A similar unresponsive pattern was observed
in the hypoxic Hela cells expressing GRK2 mutants that are unable to phosphorylate HuR (Hela-A1
and Hela-K1 cells) (Figure 2A). These data supported the notion that regulation of HuR by GRK2 was
strictly dependent on its kinase activity and on previous GRK2 phosphorylation at Ser670. Consistently,
parallel to changes in the HuR levels, a clear up-regulation of S670-GRK2 phosphorylation was noted
after 2 h of hypoxia, which was sustained afterwards in both parental and Hela-WT5 cells (Figure 2B),
but not in Hela-A1 or Hela-K1 cells.
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Figure 2. pS670-GRK2 modulates hypoxia-induced HuR upregulation. ( ,B) HeLa stable cell lines
were cultured under hypoxia and the pSer670 GRK2, GRK2, and HuR levels were analyzed by
immunoblotting, at the indicated times. Values are mean ± SE fro 4–6 independent experi ents.
Upper panel: ‡ p 0.05 t5 s. parental; # p < 0.05 A1 vs. parental; * p < 0.05 K1 vs. parental; † p <
0.05 shGRK2 vs. parental (Student’s t-test). Lower panel: * p < 0.05 A1 and K1 vs. parental; † p < 0.05
A1 and K1 vs. WT5 (Student’s t-test). Detailed information about the Western blots can be found in
Figure S4.
HuR is mainly localized in the cell nucleus in basal conditions, whereas its activity in stress
conditions is tightly linked to protein cytosolic shuttling [32,36]. Akin to stress conditions such as UV
treatment [37], serum starvation [38], or heat shock [39], cytosolic translocation of the HuR protein
occurs after prolonged CoCl2 exposure, a condition mimicking hypoxic stress [35]. We observed that
GRK2-mediated HuR phosphorylation markedly affects the HuR cytoplasmic accumulation in hypoxia.
In parental Hela cells, HuR protein is mobilized from the nucleus as early as 2 h after low oxygen
exposure, in line with previous reports [40], and enhanced cytoplasmic HuR levels are still noted 24 h
afterwards (Figure 3A). Such a pattern of HuR mobilization was potentiated by over-expression of
wild-type GRK2, whereas no shuttling was observed in the cells expressing a catalytically inactive GRK2
mutant (Hela-K1) or upon GRK2 downmodulation (Hela-shGRK2). Consistent with a relevant role for
GRK2-mediated HuR phosphorylation in this process, the cytosolic redistribution of phospho-defective
HuR mutants HuR-S197A or HuR-T142/143A was markedly reduced upon exposure to hypoxia for 3
h or 6 h (Figure 3B). The combination of these mutations in the triple HuR-T142/143/197A construct
resulted in a stronger impairment of HuR shuttling (Figure 3B). None of these HuR mutations appear
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to disturb the localization of HuR in untreated cells, suggesting that GRK2 regulation specifically takes
place under stress.
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Figure 3. GRK2 affects hypoxia-dependent changes in uR subcellular distribution. (A) The indicated
HeLa stable cell lines were cultured under hypoxia, and HuR nuclear and cytosolic levels were
analyzed by immunofluorescence, at the indicated times. Values are mean ± SEM from 3–4 independent
experiments. †† p < 0.01 wt5 vs. parental; ‡ p < 0.05 ‡‡‡ p < 0.001 K1 vs. parental; ** p < 0.01
shGRK2 vs. parental (Student’s t-test). Representative images are shown. Scale Bar = 10 µm.
(B) HeLa cells were transiently transfected with HA-HuR WT, HA-HuR-S197A, HA-HuR-T142/143A,
or HA-HuR-T142/143A-S197A, and was cultured under hypoxia for the indicated times. Localization of
HA-tagged HuR was assessed by immunofluorescence and the nuclear and cytosolic levels were
quantified. Values are mean ± SD from two independent experiments. ‡‡ p < 0.01 S197A vs. wt;
† p < 0.05 †† p < 0.01 T142/142A vs. wt; *** p < 0.001 T142/143A-S197A vs. wt; (two-way ANOVA).
Representative images are shown. Scale Bar = 7 µm.
Overall, these results indicated that GRK2-mediated phosphorylation at the residues located in
the different domains of HuR can modulate the cellular levels and the cytoplasmic localization of HuR
protein, in response to hypoxia.
2.4. GRK2 Phosphorylation of HuR Is Required for HIF-1α Upregulation in Response to Hypoxia
Central to cellular hypoxia is the upregulation of HIF-1α, which is in turn required for the
transcriptional induction of genes involved in metabolism, angiogenesis, or survival [5,6,41]. In addition
to protein stabilization, HuR-mediated translational control of HIF-1α mRNA is an important
mechanism accounting for HIF-1α protein accumulation, in response to short-term hypoxia [42,43].
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Interestingly, nuclear levels of HIF-1α after 4 h of hypoxia were markedly potentiated in the presence
of extra GRK2 (HeLa-WT5 cells), compared to parental Hela cells. By contrast, such HIF-1α nuclear
accumulation was impaired in the Hela cells overexpressing either GRK2-K220R or GRK2-S670A
mutants, both unable to phosphorylate/mobilize the HuR protein (Figure 4A).
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Figure 4. GRK2 kinase ctivi y is required for HuR-ind regulation of HIF1α. (A) HeLa stable
cell lin s wer cultu d under hypoxia for 2 h and HIF1α levels were ana yz d by immunofluorescence.
Values are mean± SEM (fold-change over parental cells in normoxia) from 3–4 independent experiments.
* p < 0.05 (Student’s t-test) comparing the changes in hypoxic HIF1α levels in Hela stable cells lines,
with those observed in hypoxic parental cells. Representative images are shown. Scale Bar = 10 µm.
(B) HeLa cells were transiently transfected with pcDNA3 as empty vector (EV), HA-HuR WT, or
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HA-HuR-T142/143A-S197A, and cultured for 4 h under hypoxia. Total lysates were then
immunoprecipitated with either an HA antibody or control IgGs. RNA was purified from
immunoprecipitates and used for qRT-PCRs. GAPDH was used as an endogenous control. The graph
shows fold differences in transcript abundance (mean ± SEM in two independent experiments
performed in triplicates). ** p < 0.01 hypoxic vs. normoxic WT; * p < 0.05 hypoxic triple mutant vs.
hypoxic WT (two-way ANOVA). The expression levels of the different HA-HuR proteins analyzed by
immunoblotting are shown below. (C) HeLa cells were transiently transfected with pcDNA3 as empty
vector (EV), HA-HuR WT, or HA-HuR-T142/143A-S197A, and was cultured under hypoxia for the
indicated times. p21 and endogenous and overexpressed HuR levels were analyzed by immunoblot.
A non-specific band was used as the loading control. Values are mean ± SEM from two independent
experiments. Detailed information about the Western blots can be found in Figure S5.
These results suggested that GRK2-phosphorylated HuR could be more efficient in binding to
HIF-1α mRNA or in regulating its decay or translation rates.
Then, we performed RNA immunoprecipitation (RIP) assays to detect HuR-HIF-1α mRNA
complexes in Hela cells that were overexpressing HA-tagged constructs of HuR. As shown in Figure 4B,
circa 2.7-fold enrichment in HuR-bound HIF-1α mRNA was found in the hypoxic cells, as compared
to the normoxic cells. In contrast, no significant hypoxia-induced increase in the binding of the
HuR-T142/T143A-S197A mutant to HIF-1α mRNA was noted. The specificity of these responses was
assessed using the non-HuR target GAPDH mRNA and control IgG immunoprecipitates, in parallel
experiments (Figure 4B). These data strongly supported the importance of GRK2-mediated HuR
modulation in the activation of the HuR/HIF-1α axis in hypoxia.
It has been proposed that stress-induced HuR might not bind with identical affinities to its
mRNA targets [40], suggesting an HuR target “prioritization” in response to specific stress stimuli.
Interestingly, the hypoxia-induced protein levels of p21, a well-known HuR target [34] was not altered
by the HuR-T142/T143A-S197A expression (Figure 4C), thereby suggesting that phosphorylation of
HuR by GRK2 alone or together with other hypoxia-induced kinases, does not necessarily affect other
HuR targets.
2.5. GRK2 Fosters the HuR/HIF-1α Axis and a Pro-Lymphangiogenic Response in the Normoxic Breast
Luminal Cancer Cells
Expression of the ELAVL1 (HuR) and ADRBK1 (GRK2) genes showed a direct correlation in
breast cancer patients inspected with the web tool CANCERTOOL (Figure S6A). A significant positive
association in hormone-stratified cohorts was found only in estrogen-positive tumors (Figure S6B).
No association of ELAVL1 and ADRBK1 co-expression was evidenced with the molecular subtypes
of breast cancer “basal-like”, “normal-like” or “HER2-enriched” in the three independent cohorts,
whereas a significant direct correlation was noted in the luminal subtype (Figure S6C).
Therefore, we used the cell line MCF7, a model of estrogen receptor (ER)-positive and luminal A
human breast tumors engineered to express different dosages of GRK2 [21], and further characterized
the effects on HuR. In basal conditions, cells overexpressing GRK2 (MCF7-GRK2) displayed a marked
increase in total HuR protein levels, compared to parental MCF7 cells, whereas the opposite effect was
observed upon GRK2 down-regulation in MCF7-shGRK2 cells (Figure 5A). Basal cytosolic translocation
of HuR was higher in MCF7-GRK2 cells compared to parental cells, as inferred from the significant
reduction of nuclear HuR levels, in spite of the global upregulation of the protein (Figure 5B).
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Figure 5. GRK2 modulates HuR levels and cytoplasmic shuttling, HIF1-α distribution, and VEGF-C
secretion in luminal breast cancer cells. (A,B) Whole lysates or nuclear extracts from MCF7 cells stably
expressing GRK2-wt or shGRK2 were used to analyze the HuR levels by immunoblot. Values are mean
± SEM from 3–4 independent experiments. * p < 0.05 ** p < 0.01 (Student’s t-test). Representative blots
with loading controls are shown. (C) MCF7 stable inducible cell lines were treated with tetracyclin
(Tet) to induce the expression of the indicated GRK2 mutants. HuR nuclear levels were analyzed by
immunoblot. Values are mean ± SEM from two independent experiments. * p < 0.05 (Student’s t-test).
Representative blots with loading controls are shown. (D,E) HIF1-α distribution and VEGF-C secretion
levels were analyzed in parental MCF7 cells or in derived cells lines stably overexpressing GRK2 or
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a silencing construct (shGRK2) of the kinase. (D) HIF1-α and DAPI staining was analyzed by
immunofluorescence; distribution of intensity values is shown. Values are distribution percentages of
cells with HIF1-α intensity values over, within, or below the mean intensity. Representative images are
shown. * p < 0.05; ** p < 0.01 (Student’s t-test) when each category (over, within, below) in MCF7-GRK2
and MCF7-shGRK2 cells is compared to parental ones. Scale Bar = 25 µm. (E) ELISA-measured VEGF-C
secretion values are shown (mean ± SEM from 3 independent experiments). * p < 0.05 (Student’s t-test).
Detailed information about the Western blots can be found in Figure S7.
This effect depended on the GRK2-dependent phosphorylation of HuR, as the inducible
over-expression of GRK2-S670A did not trigger a reduction in nuclear HuR levels, whereas a kinase
mutant mimicking the positive regulatory S670 phosphorylation event (GRK2-S670D) decreased the
nuclear HuR levels akin to the wild-type GRK2 protein (Figure 5C).
We next investigated whether GRK2-dependent HuR modulation in MCF7 cells might affect
HIF-1α nuclear distribution. As expected in tumor cells [44], normoxic MCF7 cells had a constitutive
elevation of HIF-1α protein in the nucleus. Levels of HIF-1α protein display cell-to-cell variations, with
a Gaussian distribution when the cells were stratified in subgroups, according to staining intensity,
ranging from no signal (0) to maximal signal (800), with steps of 100 arbitrary units, peaking at the
average intensity of 364.40 ± 39 (mean ± SD) arbitrary units (mean gray value). We then grouped
the stratified cell population according to the proportion of cells with intensities in the range of the
average value (34.8 ± 2.4%), above the average value (11.7 ± 4.8%), or below the average value (53.5 ±
6.1%) (Figure 5D). Interestingly, the overexpression of GRK2 did not affect the average intensity of
nuclear HIF-1α protein (382.58 ± 17 arbitrary units), but markedly altered the distribution of cells
around this value. Thus, the proportion of cells with HIF-1α levels higher than the average value was
increased circa 3-fold, while those with lower levels were reduced circa 5.5-fold. Conversely, in the
MCF7-shGRK2 cells, the average intensity of the HIF-1α protein (422.25 ± 23) was within the range of
the parental cells, but the proportion of cells with HIF-1α a level over this value was reduced 2-fold
(Figure 5D). Altogether, these results suggested that the increased expression of GRK2 noted in the
breast cancer cell lines and in patients, would also contribute to tumor progression by fostering the
cellular mechanisms that induce and stabilize the HIF-1α protein in normoxia.
A main pro-carcinogenic effect of the HIF-1α factor is the induction of angiogenesis and
lymphangiogenesis through the activation of transcription of the VEGF family members [41,45].
Of note, the secretion of VEGF-C, a potent inducer of lymphatic vessels through which breast cancer
cells often disseminate [46,47] was strongly increased in the MCF7 cells overexpressing GRK2 as
compared to the parental cells, and conversely secretion was reduced upon GRK2 downregulation
(Figure 5E). Therefore, it is tempting to suggest that GRK2 might impact VEGF-C expression via
pathways downstream of HuR phosphorylation to foster lymphangiogenesis and metastases of luminal
breast cancer cells.
2.6. Adrenergic Stress Induces a HuR/HIF1-α Hypoxia-Like Response in MCF7 Breast Cancer Cells in a
GRK2-Mediated Manner
The effects of GRK2 on the HuR/HIF1-α axis in MCF7 cells suggested that stressful or
microenvironment conditions other than hypoxia might also contribute to foster this tumorigenic
pathway. In this context, it is known that adrenergic stimulation promotes ERK-mediated
phosphorylation of GRK2 on Ser670 in different cellular systems [48] and also strengths hypoxic
signaling via HIF1-α accumulation in a GRK2-dependent manner in normoxic endothelial cells [12].
In addition, compelling evidence demonstrates that chronic adrenergic stress is involved in breast
cancer progression [49,50].
Therefore, we addressed whether chronic β2-adrenergic receptor stimulation promoted HuR
regulation by GRK2 in MCF7 breast cancer cells. Isoproterenol challenge upregulated total HuR
protein levels in both parental and MCF7-GRK2 cells, but not in GRK2-silenced cells (Figure 6A).
Isoproterenol also triggered parallel changes in GRK2 protein, suggesting that adrenergic effects on
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HuR levels involve GRK2. In addition, isoproterenol stimulation also promoted a reduction of HuR
nuclear protein levels in parental cells, and this effect was potentiated in the presence of extra kinase
in MCF7-GRK2 cells (Figure 6B). However, isoproterenol treatment failed to promote the nuclear
exit of HuR in MCF7-shGRK2 cells, indicating that GRK2 activity is required for HuR mobilization.
Consistent with the increased mobilization of nuclear HuR, nuclear HIF1-α protein was upregulated
after 48 h of βAR stimulation in cells overexpressing GRK2, compared to parental cells (Figure 6C).
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Figure 6. Chronic adrenergic stress leads to IF1α accumulation through GRK2 and HuR
upregulation in luminal breast cancer cells. Adrenergic signaling facilitates nuclear export of HuR
in a GRK2-dependent manner. MCF7-luc (control MCF7 cells) and cells stably expressing GRK2-wt
or shGRK2 were treated with 50 µM isoproterenol for the indicated times to induce adrenergic
stress. Total GRK2 and HuR levels (A) and nuclear HuR levels (B) were analyzed by immunoblot
with the indicated loading controls. (C) HIF1-α and DAPI nuclear marker levels were analyzed by
immunofluorescence. Representative images are shown (scale bar, 25 µm). All values are mean ± SEM
from three independent experiments. * p < 0.05, ** p < 0.01, ***p < 0.001 (Student’s t-test). Detailed
information about the Western blot can be found in Figure S8.
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Overall, our results point that the GRK2/HuR/HIF-1α axis is potentiated in response to hypoxic
and adrenergic stresses, thus emerging as a relevant pro-tumorigenic module.
3. Discussion
In this paper, we identified GRK2 as a modulator of the HuR/HIF-1α axis in relevant pathological
settings. We uncovered that HuR is a GRK2 substrate, requiring prior phosphorylation of GRK2
at its Ser670 regulatory site. Phosphorylation by GRK2 enhances the HuR levels and the cytosolic
shuttling of HuR upon hypoxic conditions, favoring its binding to HIF-1α mRNA and increased nuclear
accumulation of this central modulator of hypoxia-driven pathways. In the MCF7 cells, a cellular
model of luminal A breast cancer in which upregulation of GRK2 and HuR frequently concur, GRK2
increased the total and basal cytosolic HuR protein levels, which correlated with a higher nuclear
distribution of HIF-1α and enhanced secretion of the lymphoangiogenic factor VEGF-C in normoxic
conditions. Moreover, chronic adrenergic stimulation fosters the HuR/HIF1-α module in MCF7 cells
through GRK2 (Figure 7), which could facilitate survival of malignant cells even before the expanding
tumor mass become hypoxic, and could also improve the adaptation of tumor cells to the hypoxic
environment of lymphatic vessels and to other tumor-related stresses.
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the main HuR protein pool is located in the nucleus. Hypoxia or adrenergic signaling facilitates GRK2
phosphorylation at Ser670, enabling uR phosphorylation by GRK2, thus increasing uR nuclear
export. Cytosolic uR protein binds to and stabilizes IF1-α R , increasing protein translation
and IF1-α function as a transcription factor. As a consequence, transcription and protein secretion of
the VEGF-C angiogenic factor would be enhanced (scheme created with BioRender).
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Ser670 phosphorylation is an emerging regulatory switcher in GRK2 substrate specificity and
partner association [18]. Context-specific ERK1/2-dependent GRK2 Ser670 phosphorylation is necessary
for GRK2 to phosphorylate HDAC6 [21,28], to disrupt its interaction with GIT1 [51], or to allow its
HSP90-mediated localization to the mitochondrial membrane [52]. A variety of stimuli, including
growth factors [28,29], adrenergic and other GPCR ligands [53], ischemia [54], or hypoxic conditions
(this manuscript) can trigger GRK2 phosphorylation at this residue via ERK1/2 stimulation, which is
also triggered by hypoxic mimetics [55]. Therefore, it is likely that enhanced ERK1/2 activity in
response to different environmental factors would switch on the ability of GRK2 to phosphorylate and
modulate HuR.
We have identified residues within the hinge region (S197) and the RRM2 domain (T142/T143) as the
main targets of GRK2-mediated HuR phosphorylation, and mutations preventing such modifications
specifically impair hypoxia-induced HuR cytoplasmic shuttling in HeLa cells, without altering its basal
localization. Moreover, the triple HuR-T142/143/197A mutant also displays reduced binding to HIF-1α
mRNA in hypoxic conditions.
Several mechanisms might underlie the observed effects of GRK2 on HuR functionality.
Enhanced cytosolic levels of GRK2-phosphorylated HuR might be a consequence of increased nuclear
export/decreased nuclear import or fostered cytoplasmic retention. The long hinge region (aa 187–243)
includes the HuR Nucleocytoplasmic Shuttling (HNS) sequence (aa 205–237) containing both nuclear
localization and nuclear export determinants [30–33,56]. This HNS resembles a consensus bipartite
Nuclear Localization Signal, NLS sequence, with two clusters of the basic residues near the N-terminus
(aa 205–206 and aa217–219), being the first of the ones critical for nuclear targeting [57]. Introduction of
a negative charge by phosphorylation at S197 might reduce the electrostatic potential of the neighboring
basic lysine residues (aa 205–206), which are key for the interaction with the import machinery and
favors the nuclear exit. Additionally, phosphorylation of HuR on S197 might inhibit its interaction
with trans-acting factors that facilitate its translocation through the nuclear pore complex [30,56],
thus favoring cytoplasmic retention. The hinge region of HuR (aa 190–243) is involved in the interaction
with the nuclear protein ligands pp32 and April [58], in turn recognized by the export receptor
CRM1 [39], thereby making it feasible for the phosphorylation of S197 to improve its association to
pp32/April. Our results showing a cytoplasmic localization of HuR phosphorylated on S197 adds
complexity to these HuR trafficking regulatory mechanisms.
GRK2-mediated phosphorylation at T142/143 within the RRM2, the second HuR RNA binding
domain also fosters HuR cytoplasmic localization. It has been reported that interaction of HuR with
nuclear importin TNR2 is reduced by binding of ARE-containing RNA to HuR [56]. Since GRK2
phosphorylation increases the formation of HuR/HIF1 mRNA complexes, this could hamper the
interaction with the nuclear import machinery. In addition to TNR2 and the transporting homologue
TNR1 [56,59], the importing α/β pathway is required for nuclear import of HuR [60]. We cannot rule
out that the mechanisms whereby GRK2 regulates HuR shuttling include interference of HuR/importin
α/β complexes.
The subcellular location in which the phosphorylation of HuR by GRK2 takes place could shed
light on the GRK2-mediated modulation of HuR trafficking. HuR and GRK2 display opposite canonical
subcellular distribution at the basal conditions. Although GRK2 was initially described as a cytoplasmic
protein, its nuclear presence has also been reported [61], thus allowing HuR phosphorylation at this
location and regulation of nuclear export. Alternatively, or in addition, since HuR moves to the cytosol
under hypoxia, this would facilitate GRK2-mediated phosphorylation and decreased nuclear import
or fostered cytoplasmic retention.
Preventing HuR modification by GRK2 also results in a defective interaction with HIF1-α
mRNA. HuR phosphorylation has a notable impact on the binding of HuR to mRNA targets [24].
Conformational changes occurring on RRM1 and RRM2 regions are crucial for mRNA-binding [62,63].
Tandem RRM1-RRM2 displays prominent inter-domain flexibility, particularly affecting residues in
the linker and in the loops of RRM [63]. This flexibility allows HuR to fit around low affinity strands
Cancers 2020, 12, 1216 14 of 21
with high efficiency, enabling the recognition of many different mRNA substrates. Interestingly,
Thr142 is one of the positions in the RRM2 loop showing large chemical shift perturbations [63].
Thus, phosphorylation of Thr142 by GRK2 could favor structural flexibility in the close-bound state
of HuR by preventing some stabilizing interaction in the proximity of the inter-domain linker. It has
been proposed that binding of mRNAs bearing shorter 3′UTR with lower AU content could be more
influenced by the flexibility of RRM1-2 domains [63]. Remarkably, with 8 AU-rich motifs throughout
the 3′UTR (AREsite2 database, http://rna.tbi.univie.ac.at/AREsite), HIF1α mRNA could fit in the group
of mRNAs with greater dependence on HuR conformations. Therefore, it is tempting to suggest that
GRK2 might favor recognition of a subset of mRNAs displaying lower intrinsic affinities for HuR.
Furthermore, although we have not analyzed in-depth the mechanism whereby HuR
phosphorylation by GRK2 impacts its total protein levels, it is worth noting that phosphorylation of
RRM2 residues has been linked to HuR stabilization. Phosphorylation of Thr118 by CHK2 protects
HuR from proteasomal degradation upon heat shock [64]. Modifications at this site alter the extent
of HuR polyubiquitination, mainly assembled on Lys182, a RRM2 residue key for protein stability.
Whether phosphorylation of Thr142/143 by GRK2 has similar effects remains to be investigated.
The role of HuR in breast cancer development is well-documented in model cell lines, in vivo
animal models, and clinical studies [24,25]. The increased levels of HuR in MCF7 cells compared to
non-tumoral cells is implicated in the regulation of many genes involved in the cell cycle, survival,
and angiogenesis [38,65,66]. Our data put forward that in this luminal A breast cancer model GRK2
would foster HuR/HIF-1α pathways even in normoxic conditions. In MCF7 cells, GRK2 dosage
positively correlated with the total HuR protein levels, cytoplasmic HuR translocation, higher nuclear
distribution of HIF-1α, and increased VEGF-C secretion. Upregulation of HIF-1α in normoxia is a
feature of tumor cells [44] and different non-canonical modalities of HIF-1α modulation have been
identified [8]. We have previously shown that in MCF7 cells the activation of estrogen and growth factor
pathways converge for promoting an enhanced GRK2 expression and fostering GRK2 phosphorylation
at Ser670 [21], which would enable GRK2-meditaed HuR phosphorylation and enhanced functionality
and, thus, cooperate with other pathways in upregulating HIF-1α cascades.
HuR can modulate HIF1α mRNA via the 3′UTR region for transcript stabilization or via 5′UTR
for translation, depending on the cellular context [67,68]. It seems that the 5′UTR-based mechanism
predominates in highly malignant cells, while those based on 3′UTR-mediated stabilization do so in
less aggressive ones (such as MCF7) [69]. Thus, it is feasible that GRK2 phosphorylation of HuR in
MCF7 cells would foster the latter mechanism. Our results also point that the GRK2/HuR/ HIF1α axis
is involved in modulating the expression of VEGF-C, a critical factor for remodeling the lymphatic
network and tumor cell dissemination [45–47]. It is well-known that VEGF factors are transcriptional
targets of HIF-1α but are also HIF-1-independent post-transcriptional targets of HuR itself [70,71].
Therefore, GRK2-phosphorylated HuR might also directly modulate the VEGF-C mRNA in breast
tumor MCF7 cells.
Adrenergic stress is emerging as a relevant microenvironmental player in cancer progression [49,50].
Chronic emotional stressors increase the catecholamine levels and βAR activation in cancer cells and
increases metastatic potential [72] and levels of pro-angiogenic factors [73]. We unravel that chronic
adrenergic stimulation triggers the upregulation of both GRK2 and HuR protein levels, increases
cytoplasmic HuR and fosters nuclear HIF-1α presence, thus, mimicking a pseudo-hypoxia situation
that might contribute to tumor progression. Chronic adrenergic stimulation increases GRK2 expression
by different transcriptional and post-transcriptional mechanisms [74,75], and also to promote HuR
expression [76]. Normoxic HIF-1α accumulation in adrenergic-stimulated endothelial cells depends
on the phosphorylation of β-AR by GRK2 [12]. Our data suggest a mechanism linking β-AR activation
to a GRK2/HuR/HIF1α downstream axis (Figure 7). Upon agonist stimulation, GRK2-mediated
phosphorylation of β-AR would enable β-arrestin-dependent MAPK activation and subsequent
modification of GRK2 at S670, the key event allowing the targeting of HuR and the HIF1 cascade.
β-adrenergic stimulation is known to activate the MAPK cascade [77,78], and prolonged and high-dose
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stimulation of the β2AR induces a switch in receptor coupling from Gs to Gi, shifting the signaling to
MAPK pathways [79].
In sum, our data put forward a relevant role for the GRK2/HuR/HIF1α module in cancer cells and
in response to the adrenergic overdrive, regardless of the oxygen status. Enhanced GRK2 expression
and S670 phosphorylation status in the given tumor contexts would lead to enhanced HuR functionality,
thus, counteracting the canonical HIF protein degradation driven by prolyl hydroxylases [7,9] and
recapitulating a pseudo-hypoxic state in normoxia, as a consequence. Besides inducing the angiogenic
remodeling of tumoral stroma, GRK2-induced pseudo-hypoxia might favor cancer cell de-differentiation
and emergence of cancer stem-like cells. Pseudohypoxic cells are often observed at the tumor–stromal
interface in locally invading tumors, providing growing advantages during tumor expansion, as these
cells are more aggressive and resistant [4]. The coordinated regulation of key players in angiogenesis
such as HuR, HIF-1α, and VEGF-C suggest that upregulation of GRK2 might be a relevant event for
acquiring increased malignancy and invasiveness, and point that combined pharmacological inhibition
of GRK2 might be useful in certain cancer therapy contexts. This mechanism reinforces the notion of
GRK2 as a central oncomodulator influencing several hallmarks of cancer [22].
4. Methods
4.1. Cell Culture and Treatments
Cells were maintained in DMEM supplemented with 10% fetal bovine serum. Stable Hela
(ATCC) cells were previously described [27]. MCF7luc-F5 cells stably expressing pcDNA3-GRK2-wt or
pLKO-GRK2-shRNA (5′-GCAAGAAAGCCAAGAACAAGC-3′) and tetracycline-inducible expression
(TET-on) system for mutant GRK2-S670A or GRK2-S670D in MCF7 cell, were also previously
described [21]. GRK2 expression in the TET-on system was promoted by treating the cells with
1 µg/mL tetracyclin for 24 h. Hypoxia (1% O2) was achieved in an Invivo2 400 hypoxia Workstation
(Baker Ruskinn, USA). Isoproterenol (50 µM) was supplemented with 1 mM ascorbic acid and 20 mM
HEPES pH 7.5.
4.2. Plasmids and Cell Transfection
Plasmids encoding HA-HuR WT were previously described [33]. HA-HuR-S197A,
HA-HuR-T142/143A, or HA-HuR-T142/143A-S197A were generated using QuickChange® Lightning
site-directed mutagenesis kit (Thermo Fisher, Waltham, MA, USA). HeLa cells (70%–80% confluent
monolayers in 60 or 100 mm dishes) were transiently transfected using the lipofectamine/plus method.
4.3. Immunoprecipitation, Western Blot, Dot Blot, and ELISA
Whole cellular lysates were prepared in RIPA buffer (Tris-HCl 20 mM pH 7.5, 150 mM NaCl, 1%
Triton-X100, 0.1% SDS, 0.5% sodium deoxycholate, cocktail of protease, and phosphatase inhibitors),
as described [28]. For the analysis of nuclear and cytoplasmic pools of HuR and HIF-1α, cells were
collected in hypotonic lysis buffer (10 mM Tris–HCl, pH 7.4, 10 mM NaCl, 3 mM MgCl2, 0.3% (v/v)
Nonidet P-40, 2 mM Na3V04, 10 mM NaF, and protease inhibitors), incubated on ice for 10 min
and centrifuged at 500 ×g for 5 min to obtain the nuclear fraction. The cytoplasmic supernatant
contains the extranuclear fraction (plasma membrane, microsomal vesicles, cytoskeleton, and cytosol).
Pellets containing cell nuclei were washed in lysis buffer without Nonidet P-40 and again pelleted at 500
×g. Both fractions were solubilized in Laemmli sample buffer and resolved by SDS–PAGE. Proteins were
resolved in SDS–PAGE and transferred to nitrocellulose membranes. Cytosolic (GAPDH) and nuclear
(Nucleolin) markers were used for control loading. For the dot-blot experiments, GST-tagged GRK2
fragments (2 µg) and recombinant GRK2 full-length protein were spotted on strips of nitrocellulose and
incubated for 4 h at 37 ◦C, with GST-HuR (2 µg/mL) in the interaction buffer (20 mM Tris-HCl pH 7.5,
100 mM NaCl, 1 mM EDTA, 0.3% NP-40, 10% Glycerol, 0.5 mM NaF, and 1 mM Na3V04). Membranes
were incubated with the indicated primary antibodies—α-Actin (1:2000, Santa Cruz Biotechnology,
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Santa Cruz, CA, USA), GAPDH (1:2000, Santa Cruz Biotechnology), (pSer670-GRK2 (1:500, GeneTex,
Irvine, CA, USA), GRK2 (1:1000, Santa Cruz Biotechnology), HuR (1:000, Santa Cruz Biotechnology),
Nucleolin (1:1000, Santa Cruz Biotechnology), p21 (1:500, Santa Cruz Biotechnology), and α-Tubulin
(1:2000, Santa Cruz Biotechnology). Blots were developed using a chemiluminescent method (ECL,
Amersham, Little Chalfont, UK). Band density was quantitated by laser densitometric analysis.
VEGF-C secretion was determined in cell-conditioned media of MCF7 cells incubated in DMEM
1% FCS for 48 h, by using a Human VEGF-C Quantikine ELISA Kit (R&D Systems, Minneapolis,
MN, USA). Measurements in duplicates were normalized to the amount of the total protein in cell
lysates quantified by the Lowry method.
4.4. Immunofluorescence and Confocal Microscopy
As described in [28], 4% PFA-fixed cells were processed and incubated O/N at 4 ◦C, with primary
antibodies—HA (1:600, Cell Signaling, Leiden, The Netherlands), HIF1α (1:200, Novus Biologicals,
Centennial, CO, USA) and HuR (1:200, Santa Cruz Biotechnology). Then, coverslips were incubated
for 1 h RT with fluorescent secondary antibodies, and for 5 min with To-Pro3 (1:2000, ThermoFisher,
Waltham, MA, USA) or DAPI (1 µg/mL, Merck, Darmstadt, Germany) to stain nuclei. Finally, samples
were mounted using Mowiol-DABCO (Boston Bioproducts, Ashland, MA, USA), let to dry overnight
at RT and then stored at 4 ◦C. Images were acquired using a confocal laser microscope LSM710 (Zeiss,
Oberkochen, Germany) and the nucleus area and mean intensity values were analyzed using ImageJ
(NIH, Bethesda, MD, USA). In both the basal and stress conditions, nuclear masks were drawn using
the nuclear staining distribution pattern of HuR and were guided by the morphological features
(nucleolus, euchromatin, speckles) (Figure S9). For each cell, three measurements were made within
the nucleoplasm, excluding the HuR-negative areas corresponding to nucleoli and nuclear speckles,
or indistinctly in the cytoplasm peripheral to the nucleus. Fluorescence intensity values were corrected
for background staining. The ratio of the mean cytoplasmic (C) to nuclear (N) value was calculated for
each cell. Average C/N values from all cells within a field were pooled for subsequent plotting and
comparative analysis. Cells from 10 different randomly acquired fields (40× or 63×) were measured for
each cell type and condition. Average values from all cells within a field were pooled for subsequent
plotting and analysis.
4.5. Kinase Activity Assays
In vitro kinase assays with wild-type, S670A or K220R GRK2 full-length (50 nM); and WT,
T142/143A or S197A GST-tagged HuR recombinant proteins (50–250 nM for Km value and 100 nM
for the rest) were performed, as described [28]. The Michaelis constant (Km) was estimated by
double-reciprocal plot analysis of three independent experiments.
4.6. Mass Spectrometry Analysis
GRK2 (50 nM) and GST-HuR (100 nM) were incubated in the presence of cold ATP, as detailed
above and resolved by SDS–PAGE. The band corresponding to full-length GST-HuR was digested
by trypsin and chymotrypsin, and the fragments were analyzed using LC–MS/MS in the ‘CBMSO
PROTEIN CHEMISTRY FACILITY’ that belonged to the ProteoRed network, PRB2-ISCIII, supported
by the grant PT13/0001.
4.7. RNA Immunoprecipitation
RNA Immunoprecipitation (RIP) assays were performed, as previously described [80]. Whole-cell
lysates (500 µg) were incubated with a suspension of Protein A/G PLUS-Agarose, precoated with 15
µg of either IgG or anti-HA antibody-conjugated agarose beads (all from Santa Cruz Biotechnology).
Bound mRNA was purified from immunoprecipitants, retrotranscribed by RT-PCR, and the HIFα
mRNA content was measured by real-time PCR analysis and normalized to GAPDH mRNA bound in
a nonspecific manner to IgG.
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4.8. Bioinformatics Analysis of HuR and GRK2 Expression in Human Breast Tumors
Pairwise correlation of gene expression ELAVL1 (HuR protein) and ADRBK1 (GRK2 protein)
levels in breast tumors was calculated and represented using the CANCERTOOL webtool [81].
Pearson correlation test was applied to analyze the relationship between paired genes, and the
correlation coefficient and p-values were adjusted using the Benjamini–Hochberg method. Datasets with
a correlation coefficient greater than 20% (−0.2 < R < 0.2) and a p-value lower than 0.05 were considered.
4.9. Statistical Analysis
Data analysis was performed using the GraphPad Prism for Windows. Means between groups
were compared by two-way or one-way ANOVA with Bonferroni’s or Tukey’s post-hoc test, or with
unpaired Student’s t-test, as indicated in the figure legends. All results are expressed as mean ± SEM.
5. Conclusions
An active GRK2/HuR/ HIF-1α module, particularly in estrogen-positive luminal A breast tumors
could facilitate survival of malignant cells, even before the expanding tumor mass becomes hypoxic,
and also improves the adaptation of tumor cells to the hypoxic environment of lymphatic vessels and
to other tumor-related stresses, such as chronic over-activation of the adrenergic system, in order to
foster tumor progression.
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